Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  DietType 2 DiabetesAging & DiabetesIssue 612

Decaffeinated Coffee Might Boost Brain Power for Type 2 Diabetes

Decaf coffee was found to improve glucose energy metabolism in the brain in mouse studies....

Advertisement

Type 2 diabetes is linked to cognitive decline, dementia and Alzheimer's disease that stems from impaired breakdown of glucose needed for optimal brain function. The study is the first to show decaffeinated coffee might prevent and treat declining memory associated with Type 2 diabetes, aging and neurodegenerative disorders.

For the study researchers gave mice induced to develop diabetes a decaf coffee supplement for five months and then evaluated the mouse brain's genetic response to the treatment. The result was increased ability of the brain to metabolize glucose.

Giulio Maria Pasinetti, MD, PhD, Professor of Neurology, and Psychiatry, at Mount Sinai School of Medicine, said it's important to find ways to prevent cognitive decline from neurodegenerative diseases. Studies show pathological changes in the brain occur decades before Alzheimer's and other diseases develop. He also notes the study shows not all of the health benefits associated with coffee come from caffeine.

It's important to note that coffee can have negative cardiovascular effects and is linked to elevated blood pressure and cholesterol levels, making consumption risky for some.

Pasinetti plans to explore whether decaffeinated coffee could be useful as a dietary supplement in humans to prevent or even treat memory loss associated with Type 2 diabetes and other brain disorders.

Nutritional Neuroscience H. Lap et al.Nov. 2011

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 08 February, 2012 and appeared in  DietType 2 DiabetesAging & DiabetesIssue 612

Past five issues: SGLT-2 Inhibitors Special Edition July 2015 | Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
Posted July 17, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
Ancestral Diets Can Determine Vulnerability to Type 2 Diabetes
Posted July 17, 2015
Can the Insulin Patch Become a Reality?
Posted July 03, 2015
Two Gene Mutations Identified in Increased Risk of Obesity and Diabetes
Posted July 23, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you have any patients on a dual therapy of a DPP-4 and a SGLT-2 who have reached their goal A1c?

CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology